Cardiology

Biotech

An FDA panel backed Amarin’s fish oil drug. Here’s a detailed breakdown of the debate

By Adam Feuerstein and Matthew Herper

Biotech

FDA documents point to a broadened approval for Amarin’s heart pill Vascepa

By Matthew Herper and Adam Feuerstein

Health

Cholesterol levels dropping in U.S., but many still need care

By Associated Press

Biotech

Fibrogen discloses new data that eases heart-safety concerns about experimental anemia pill

By Adam Feuerstein

Biotech

Cleveland Clinic’s Nissen denies any communication with FDA about Amarin’s Vascepa

By Matthew Herper

Pharma

The return of Vioxx: Can a drug once deemed deadly be relaunched to treat rare disease?

By Damian Garde

Health

An AI startup, led by 23andMe veteran Andy Page, tries to take better pictures of the heart

By Matthew Herper

Pharmalot

Sandoz halts global distribution of heartburn med over carcinogen link while Canada tells other manufacturers to stop

By Ed Silverman

Pharmalot

FDA and EMA are now probing carcinogen in Zantac and other heartburn meds

By Ed Silverman

Health

Some 9/11 firefighters may have higher heart risks now

By Associated Press

Biotech

Regeneron drug proves effective in genetic form of high cholesterol

By Matthew Herper and Damian Garde

Biotech

Amarin now says FDA plans outside panel review of its Vascepa heart drug, delaying approval decision

By Adam Feuerstein

Health Tech

5 ways artificial intelligence is already changing cardiac care

By Casey Ross

Health

Study: Millions should stop using aspirin for heart health

By Associated Press

In the Lab

A family’s medical mystery sheds light on the surprising ways disease-causing genes can be inherited

By Andrew Joseph

In the Lab

Attempt to replicate clinical trials with real-world data generates real-world criticism, too

By Matthew Herper

Business

Amarin raises sales guidance for heart drug Vascepa, hires more sales reps for larger marketing push

By Adam Feuerstein

First Opinion

In a medical emergency, who in your social network will call for help quickest?

By Amar Dhand

In the Lab

‘Alexa, are you listening?’ An experimental tool warns of cardiac arrest by monitoring breathing

By Diana Cai

Health

Patients whose blood pressure only spikes at the doctor’s office are twice as likely to die of a heart attack or other cardiac event

By Ruth Hailu

Health

Former NFL players die at a faster rate than other professional athletes, study finds

By Shraddha Chakradhar

Adam's Take

Fibrogen’s obtuse disclosures about anemia pill raise concerns over heart safety, putting approval at risk

By Adam Feuerstein

The Readout LOUD

Listen: Pharma felonies, cardiac CRISPR, and a strange day at the FDA

By Damian Garde and Adam Feuerstein

Biotech

With a superstar cardiologist as its CEO, new CRISPR company targets heart disease

By Sharon Begley

Health

A machine learning device, meant to monitor the chronically ill, moves into homes

By Casey Ross

With $9.7 billion acquisition, Novartis bets that heart drugs are coming back

Amarin releases interim EVAPORATE data — and mineral oil makes another appearance

Big study casts doubt on need for many heart procedures

Apple launches virtual health studies aiming to enroll hundreds of thousands of customers

An FDA panel backed Amarin’s fish oil drug. Here’s a detailed breakdown of the debate

FDA documents point to a broadened approval for Amarin’s heart pill Vascepa

Cholesterol levels dropping in U.S., but many still need care

Fibrogen discloses new data that eases heart-safety concerns about experimental anemia pill

Cleveland Clinic’s Nissen denies any communication with FDA about Amarin’s Vascepa

The return of Vioxx: Can a drug once deemed deadly be relaunched to treat rare disease?

An AI startup, led by 23andMe veteran Andy Page, tries to take better pictures of the heart

Sandoz halts global distribution of heartburn med over carcinogen link while Canada tells other manufacturers to stop

FDA and EMA are now probing carcinogen in Zantac and other heartburn meds

Some 9/11 firefighters may have higher heart risks now

Regeneron drug proves effective in genetic form of high cholesterol

Amarin now says FDA plans outside panel review of its Vascepa heart drug, delaying approval decision

5 ways artificial intelligence is already changing cardiac care

Study: Millions should stop using aspirin for heart health

A family’s medical mystery sheds light on the surprising ways disease-causing genes can be inherited

Attempt to replicate clinical trials with real-world data generates real-world criticism, too

Amarin raises sales guidance for heart drug Vascepa, hires more sales reps for larger marketing push

In a medical emergency, who in your social network will call for help quickest?

‘Alexa, are you listening?’ An experimental tool warns of cardiac arrest by monitoring breathing

Patients whose blood pressure only spikes at the doctor’s office are twice as likely to die of a heart attack or other cardiac event

Former NFL players die at a faster rate than other professional athletes, study finds

Fibrogen’s obtuse disclosures about anemia pill raise concerns over heart safety, putting approval at risk

Listen: Pharma felonies, cardiac CRISPR, and a strange day at the FDA

With a superstar cardiologist as its CEO, new CRISPR company targets heart disease

A machine learning device, meant to monitor the chronically ill, moves into homes